What Chiesi’s $1.9bn KalVista deal reveals about the next phase of rare disease consolidation
Rare disease M&A is shifting from science risk to launch execution. Chiesi’s KalVista deal puts oral HAE therapy at the center.
Will pediatric KONFIDENT-KID data accelerate KalVista’s sebetralstat approval in hereditary angioedema?
KalVista’s sebetralstat pediatric trial data heads to Madrid. What it means for the HAE on-demand market and a 2026 FDA filing. Read the analysis.
Why BioCryst’s Astria acquisition reshapes long-acting competition in hereditary angioedema prophylaxis
BioCryst completes its Astria acquisition to expand long-acting hereditary angioedema leadership. Find out what this means for HAE treatment competition.
Can KalVista’s refill-led EKTERLY growth signal a new standard in on-demand HAE care?
KalVista’s oral HAE drug EKTERLY hit $49M in 2025 sales. Discover what strong refill demand and global expansion mean for rare disease treatment models.